stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) EPS (diluted)
Palvella Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$3.71, compared with −$7.83 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$4.83. Over the past ten years it has ranged from −$56.80 (fiscal 2021) to $2.17 (fiscal 2023); the current reading is higher than 91% of that period. Palvella Therapeutics, Inc. ranks 440th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.71 | — |
| FY2024 | −$7.83 | — |
| FY2023 | $2.17 | — |
| FY2022 | −$36.00 | — |
| FY2021 | −$56.80 | — |
| FY2020 | −$54.40 | — |
| FY2019 | −$44.80 | — |
| FY2018 | −$40.00 | — |
| FY2017 | −$32.00 | — |
| FY2016 | −$44.00 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$1.52 | — |
| Mar 2026 | −$1.20 | — |
| Dec 2025 | −$1.08 | — |
| Sep 2025 | −$1.03 | — |
| 41 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $2.29 |
| ADMA ADMA Biologics Inc compare | $0.77 |
| VCEL Vericel Corporation compare | $0.65 |
| IMNM Immunome, Inc. compare | −$2.53 |
| PHVS Pharvaris N.V. compare | −$3.05 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
| PVLA Palvella Therapeutics, Inc. | −$4.83 |
| VERA Vera Therapeutics, Inc. compare | −$5.86 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on PVLA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement